RSS Atom • ISSN 1472-4683 • Subscribe • About
Treatment alerts
- Milk thistle (silymarin) and darunavir/ritonavir PK and drug interactions - Treatment alerts - PK Workshop 13th 2012 - 21 May 2012
- Pfizer issue Dear Doctor letter over EMS content in US formulation of nelfinavir Treatment alerts - 3 September 2007
- Dear Doctor letter issued in the U.S. relating to 14 reports of intracranial haemorrhage (ICH) events with tipranavir/r Treatment alerts - 3 August 2006
- Important renal safety information regarding the use of tenofovir and Truvada Treatment alerts - 13 April 2006
- Drug-induced hepatitis in healthy volunteers receiving rifampicin 600mg daily in combination with ritonavir 100mg and saquinavir 1000mg twice daily (boosted saquinavir) Treatment alerts - 18 April 2005
- New European recommendations regarding the co-administration of ddI (Videx) and tenofovir DF (Viread) Treatment alerts - 18 April 2005
- Important new pharmacokinetic data demonstrating that atazanavir sulfate (Reyataz) combined with ritonavir (Norvir) and proton pump inhibitors should not be coadministered Treatment alerts - 29 March 2005
- Important new clinical data: potential early virologic failure associated with the combination antiretroviral regimen of tenofovir disoproxil fumarate, didanosine, and either efavirenz or nevirapine in HIV treatment-naive patients with high baseline viral loads Treatment alerts - 31 January 2005
- A round-up of news about access to treatments, with links to sources Treatment alerts - 29 July 2004
- Risk factors for severe, life-threatening and fatal hepatotoxicity with nevirapine Treatment alerts - 3 April 2004
- Important safety information: high rate of virologic failure in patients with HIV infection treated with a once-daily triple NRTI combination containing ddI, 3TC, and tenofovir DF Treatment alerts - 1 November 2003
- Important new pharmacokinetic data for atazanavir sulfate (Reyataz) in combination with tenofovir disoproxil fumarate (Viread) Treatment alerts - 1 October 2003
- EMEA public statement on early virologic non-response in patients with HIV infection treated with tenofovir in combination with lamivudine and abacavir Treatment alerts - 1 September 2003
- Rapidly ascending neuromuscular weakness associated with nucleoside analogues Side effects - Treatment alerts - 2 October 2001
- Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures – worldwide, 1997-2000 Treatment alerts - 17 January 2001
- US FDA and Bristol-Myers Squibb issue caution for combination HIV therapy with stavudine (d4T) and didanosine (ddI) in pregnant women PMTCT and maternal health - Treatment alerts - Women's health - 17 January 2001
- Abacavir hypersensitivity cases following an interruption of therapy Treatment alerts - 16 September 2000
- Severe Hypersensitivity Reactions following reintroduction with Ziagen (abacavir sulphate) Treatment alerts - 16 August 2000